Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000445 · ClinicalTrials.gov registry record · Phase 4
Use of Naltrexone in a Clinical Setting
A Phase 4 study, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
NCT00000445 is a Phase 4 study that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 300 participants.
The verdict
NCT00000445, a Phase 4 study, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
Study Summary
This 12-week trial will compare individuals receiving naltrexone or placebo plus substance abuse counseling therapy versus those receiving only substance abuse counseling therapy in a rural, nonacademic setting. A followup period of 12 months is included. The effect on service utilization and the cost of the addition of naltrexone to treatment services for alcohol dependence also will be assessed. The study will expand existing research concerning the effectiveness of naltrexone in clinical trials versus a clinical setting.
Interventions
- DRUG naltrexone (Revia)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Est. Completion | 2002-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000445
The ClinicalTrials.gov registry entry for NCT00000445 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which naltrexone (Revia) is the first listed.
NCT00000445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000445 about?
NCT00000445 is a clinical study titled "Use of Naltrexone in a Clinical Setting". This 12-week trial will compare individuals receiving naltrexone or placebo plus substance abuse counseling therapy versus those receiving only substance abuse counseling therapy in a rural, nonacademic setting. A followup period of 12 months is included. The effect on service utilization and the co...
What is the current status of trial NCT00000445?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. Estimated completion is 2002-09.
What interventions are being tested in trial NCT00000445?
The interventions under investigation include: naltrexone (Revia) (DRUG).
Who is sponsoring clinical trial NCT00000445?
This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.